Clinical trial NCT04255160: Impact of Estradiol on Endothelial Function in Peri-Menopausal Women
Official title: Impact of Estradiol on Endothelial Function in Peri-Menopausal Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Perimenopause
Vasodilation
Estrogen
Keywords: Perimenopause
Vasodilation
Estrogen
Lead sponsor: University of Delaware
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2020-02-05
Enrollment: 80
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 58
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women. This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age and in response to E2 administration.

Detailed description: Cardiovascular disease (CVD) is the leading cause of death in women. Although overall CVD-related mortality has declined, there has been an increase in CVD mortality in women aged 35-54 years, prior to menopause. It is unclear what contributes to this increased mortality rate, and is a significant problem for women's health. Endothelial function is considered a biomarker of cardiovascular health; declines in endothelial function are considered a precursor to the development of atherosclerosis and CVD. Thus, changes in endothelial function in women as they advance through reproductive stages towards menopause may play a role in the greater prevalence of CVD mortality. However, very few studies have focused on cardiovascular health in women leading up to menopause, during the PERI transition. The PERI period is a critical time point where reproductive hormones and ovarian function change rapidly. Recent data demonstrate that endothelial function begins to decline during PERI. Furthermore, despite women being of similar biological age, significant differences in endothelial function were noted when classified based on reproductive age - specifically between early PERI and late PERI. These data show that the decline initially occurs in the early PERI phase, making this a key time point for intervention to offset the future development of CVD. Our central hypothesis is that increased Endothelin-1 (ET-1) and a loss of Endothelin-1 B (ETB) mediated vasodilation play a primary role in contributing to impaired endothelial function with advancing reproductive age. We will assess macro- and micro- vascular endothelial function, assess intracellular ET-1 protein and ETB receptor expression in harvested endothelial cells from peripheral veins, and use the cutaneous circulation as an in vivo model to explore the receptor mechanisms (ETBR and ETAR) in early and late PERI in response to E2 or placebo.

Eligibility criteria: Inclusion Criteria:

* Peri-menopausal women between 40-58 years of age with variable cycles as defined by increase in cycle length of greater than 7 days within ten consecutive cycles, or amenorrhea for more than 2 months, but less than 12 months.

Exclusion Criteria:

* Women who are pregnant, planning on becoming pregnant, or are breast feeding;
* Women who have a history of cardiovascular disease, blood clots (e.g, pulmonary embolism or deep vein thrombosis), stroke, cancer, or liver disease;
* Women who have a body mass index less than 18 or greater than 35kg/m2;
* Women who use tobacco products;
* Women who's blood pressure is greater than 140/90 mmHg, have been diagnosed by a physician with hypertension or are taking medication for high blood pressure;
* Women who have a neurological disease, or diabetes;
* Women who have had a hysterectomy or have used hormones (birth control or hormone replacement) within the past 3 months;
* Women who have a latex allergy.

Primary outcomes:
measure: Vascular Endothelial Function (Flow mediated dilation or FMD)
timeFrame: Change in FMD from Baseline to Day 7
Secondary outcomes:
measure: Endothelial Cell Protein Expression
timeFrame: Change in fluorescent intensity from Baseline to Day 7
measure: Endothelin Receptor Responses
timeFrame: Change from Baseline to Day 7
Other outcomes:
Locations:
city: Newark
country: United States
facility: University of Delaware
state: Delaware
Study officials:
References: